基孔肯雅病毒感染可引发基孔肯雅热，该病毒在热带及温带的广泛区域均有流行，已成为全球性公共卫生问题。基孔肯雅热以对症治疗为主，没有特效药物，接种疫苗是预防基孔肯雅病毒感染的经济有效手段。虽然目前已有2款疫苗被批准在局部地区使用，但远不能满足高风险区对疫苗的需求。此文对基孔肯雅病毒疫苗研发现状进行综述，重点对已上市疫苗、进入临床试验阶段的疫苗和有潜力进入临床试验的疫苗进行总结。

Chikungunya virus infection can cause chikungunya hemorrhagic fever, which is prevalent in a wide range of tropical and temperate regions and has become a global public health problem. Chikungunya hemorrhagic fever is mainly treated by symptomatic treatment, and there is no specific antiviral drug. Vaccination is an economical and effective means to prevent chikungunya virus infection. Although two vaccines have been approved for use in local areas, they are far from meeting the demand for vaccines in high-risk areas. This article reviews the research and development status of chikungunya virus vaccine, focusing on vaccines on the market, candidate vaccines entering clinical trials and vaccines that have potential to enter the clinical trial.